147 related articles for article (PubMed ID: 35137936)
1. Optimized method for normal range estimation of standardized uptake values (SUVmax, SUVmean) in liver SPECT/CT images with somatostatin analog [99mTc]-HYNIC-TOC (Tektrotyd).
Piwowarska-Bilska H; Kurkowska S; Birkenfeld B
Nucl Med Rev Cent East Eur; 2022; 25(1):37-46. PubMed ID: 35137936
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.
Reilly C; Gemmell AJ; McLaughlin IM; Fleming R; Reed N; McIntosh D; Nicol A
Nucl Med Commun; 2021 Aug; 42(8):935-939. PubMed ID: 33741866
[TBL] [Abstract][Full Text] [Related]
3. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.
Yamaga LY; Neto GC; da Cunha ML; Osawa A; Oliveira JC; Fonseca RQ; Nogueira SA; Wagner J; Funari MG
Radiol Med; 2016 Mar; 121(3):225-8. PubMed ID: 26558391
[TBL] [Abstract][Full Text] [Related]
6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.
Al-Chalabi H; Cook A; Ellis C; Patel CN; Scarsbrook AF
Clin Radiol; 2018 Jun; 73(6):527-534. PubMed ID: 29397911
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of SPECT/CT scans using SUV measurement of the normal pelvis with Tc-99m methylene diphosphonate.
Wang R; Duan X; Shen C; Han D; Ma J; Wu H; Xu X; Qin T; Fan Q; Zhang Z; Shi W; Guo Y
J Xray Sci Technol; 2018; 26(6):895-908. PubMed ID: 30103368
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bone single-photon emission computed tomography (SPECT)/CT and bone scintigraphy in assessing knee joints.
An YS; Park DY; Min BH; Lee SJ; Yoon JK
BMC Med Imaging; 2021 Mar; 21(1):60. PubMed ID: 33771130
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
15. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
16. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy.
Garai I; Barna S; Nagy G; Forgacs A
Nucl Med Rev Cent East Eur; 2016; 19(2):93-8. PubMed ID: 27479887
[TBL] [Abstract][Full Text] [Related]
17. [Value of
Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
[TBL] [Abstract][Full Text] [Related]
18. [Improvement of Standardized Uptake Value Accuracy in the
Nakamura Y; Kangai Y; Abe T; Nakahara Y
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2021; 77(9):921-931. PubMed ID: 34544916
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis.
Boutsikou E; Porpodis K; Chatzipavlidou V; Hardavella G; Gerasimou G; Domvri K; Papadopoulos N; Avramidou V; Spyratos D; Kontakiotis T; Zarogoulidis K
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842586. PubMed ID: 31079574
[TBL] [Abstract][Full Text] [Related]
20. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
